Theratechnologies Inc (TH-T) Stock Predictions - Stockchase
WATCH LIST
13
Theratechnologies Inc (TH-T)

ON STOCKCHASE SINCE May 2003

biotechnology/pharmaceutical

Theratechnologies Inc

TH-T

9 watching          
Join the Discussion

Theratechnologies Inc (TH-T) SAVE Apr, 19, 2019, 9:02 am

7.03 0.09 (1.26%)

What the experts are saying about TH-T



  • All
  • Filtered
Signal Opinion Expert
PARTIAL BUY
Theratechnologies Inc(TH-T) 

January 4, 2019

Every biotech company always has some life-altering technology, and it's always way too positive. Small-mid caps like this can have big moves. Reversing a sideways trend, and breaking up to new levels, so that's positive. Maybe some movement up to $12. Take a small position, don't expose yourself too much. Support will be around $8.50, and if it breaks, start exiting.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Every biotech company always has some life-altering technology, and it's always way too positive. Small-mid caps like this can have big moves. Reversing a sideways trend, and breaking up to new levels, so that's positive. Maybe some movement up to $12. Take a small position, don't expose yourself too much. Support will be around $8.50, and if it breaks, start exiting.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Jeff Parent B.

VP & Portf, Castlemoore Inc....

Price Price
$9.480
Owned Owned
Unknown

SPECULATIVE BUY
Theratechnologies Inc(TH-T) 

August 28, 2018

Had a sharp run, then a sharp pullback. Technically it looks good here. You could buy it here. But he doesn't know this company well.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Had a sharp run, then a sharp pullback. Technically it looks good here. You could buy it here. But he doesn't know this company well.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Elliott Fishman

Director o, Trading Services Gro...

Price Price
$10.110
Owned Owned
Unknown

PAST TOP PICK
Theratechnologies Inc(TH-T) 

February 8, 2018

(A Top Pick July 10/17 - Down 13%.)  He knew it was high risk. The biggest risk would be a non-approval or delay on the process of getting a drug approved. A delay came to place. Still watch the story for the future. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick July 10/17 - Down 13%.)  He knew it was high risk. The biggest risk would be a non-approval or delay on the process of getting a drug approved. A delay came to place. Still watch the story for the future. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Gerard Ferguson

CEO & Port, Jemekk Capital Manag...

Price Price
$7.160
Owned Owned
No

TOP PICK

They are taking the profits and cash flow from their drug to introduce a second drug, expected next year. (Analysts’ target: $9.50).

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

They are taking the profits and cash flow from their drug to introduce a second drug, expected next year. (Analysts’ target: $9.50).

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Gerard Ferguson

CEO & Port, Jemekk Capital Manag...

Price Price
$8.240
Owned Owned
Yes

BUY
Canadian. Excellent phase 3 product results. A take over target, in a position of being sold right now. They have lots of cash. At this level it’s a dollar below financing. Good product. Would buy at this price.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Canadian. Excellent phase 3 product results. A take over target, in a position of being sold right now. They have lots of cash. At this level it’s a dollar below financing. Good product. Would buy at this price.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Peter Hodson

CEO & Head, 5i Research Inc....

Price Price
$7.290
Owned Owned
Yes

BUY
Excellent phase 3 results. They are a takeover target, they have lots of cash. Annoyed at management because last month they had 61 million in cash, and decided to put the company up for sale, while at the same time decided to raise money. They can't have it both ways. Nothing wrong with the product. Good one to hold and to buy. Should be stable.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Excellent phase 3 results. They are a takeover target, they have lots of cash. Annoyed at management because last month they had 61 million in cash, and decided to put the company up for sale, while at the same time decided to raise money. They can't have it both ways. Nothing wrong with the product. Good one to hold and to buy. Should be stable.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Peter Hodson

CEO & Head, 5i Research Inc....

Price Price
$7.170
Owned Owned
Yes

BUY
Theratechnologies Inc(TH-T) 

October 15, 2007

Had 2 good phase 3 trials. 2nd trial is going on right now. Long-term data was very effective. FDA approval will probably happen in the next year. Probably the best takeout candidate in a biotechnology space.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Had 2 good phase 3 trials. 2nd trial is going on right now. Long-term data was very effective. FDA approval will probably happen in the next year. Probably the best takeout candidate in a biotechnology space.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Peter Hodson

CEO & Head, 5i Research Inc....

Price Price
$12.150
Owned Owned
Yes

STRONG BUY
Theratechnologies Inc(TH-T) 

August 17, 2007

Bought today. Have had great results on their phase 3. They've done their financing, they've got their cash. Go to market probably in 2010, 2011. Likely will be acquired. Mixed view of what the drug could be worth.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Bought today. Have had great results on their phase 3. They've done their financing, they've got their cash. Go to market probably in 2010, 2011. Likely will be acquired. Mixed view of what the drug could be worth.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Peter Hodson

CEO & Head, 5i Research Inc....

Price Price
$8.490
Owned Owned
Yes

DON'T BUY
Think you are arriving at the party late on this one. He would have preferred to buy on the breakout pattern in late 2006.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Think you are arriving at the party late on this one. He would have preferred to buy on the breakout pattern in late 2006.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Bill Carrigan

Technical , Getting Technical In...

Price Price
$8.400
Owned Owned
No

BUY
Theratechnologies Inc(TH-T) 

February 6, 2007

Phase 3 shoed their drug did not have side effects. This resulted in a large move in the stock price. Now doing a financing, which will be a net positive for the stock. Could be a takeout or could be a partnership.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Phase 3 shoed their drug did not have side effects. This resulted in a large move in the stock price. Now doing a financing, which will be a net positive for the stock. Could be a takeout or could be a partnership.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Alexander Lane,

Vice Presi, Dynamic Funds...

Price Price
$8.470
Owned Owned
Unknown

WEAK BUY
Theratechnologies Inc(TH-T) 

November 17, 2005

Management team's not bad. A very, very cheap stock. Have a good balance sheet. Thinks you can make money by buying it here regardless of what happens. Would prefer a larger market cap company.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Management team's not bad. A very, very cheap stock. Have a good balance sheet. Thinks you can make money by buying it here regardless of what happens. Would prefer a larger market cap company.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Peter Hodson

CEO & Head, 5i Research Inc....

Price Price
$1.040
Owned Owned
Unknown

BUY
Theratechnologies Inc(TH-T) 

October 28, 2003

Very bullish on this stock. Has a lot of cash. A good price.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Very bullish on this stock. Has a lot of cash. A good price.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Vincent Delisle

Investment, Desjardins Securitie...

Price Price
$5.400
Owned Owned
Unknown

BUY
If you like biotechs, this could be OK. Speculative.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
If you like biotechs, this could be OK. Speculative.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Andrew McCreath

Senior Por, Sentry Select Capita...

Price Price
$6.230
Owned Owned
Unknown

Showing 1 to 13 of 13 entries
Successfully Saved Company
Successfully Saved Company
4+
JOIN THE DISCUSSION
4 comments in the last 7 days